Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: Brenner Tumor; Ovarian Carcinosarcoma; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mixed Epithelial Carcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Papillary Serous Carcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Undifferentiated Adenocarcinoma; Recurrent Fallopian Tube Cancer; Recurrent Ovarian Epithelial Cancer; Recurrent Primary Peritoneal Cavity CancerInterventions: Drug: WEE1 inhibitor MK-1775; Drug: gemcitabine hydrochloride; Other: placebo; Other: laboratory biomarker analysis; Other: pharmacological studySponsor: National Cancer Institute (NCI)Recruiting - verified September 2014
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Carcinoma | Carcinosarcoma | Fallopian Tube Cancer | Mucinous Ovarian Cancer | Ovarian Cancer | Ovaries | Research